Literature DB >> 25332606

Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature.

Jayastu Senapati1, Anup J Devasia1, Sachin David1, Marie Therese Manipadam2, Sheila Nair2, Giridhara R Jayandharan1, Biju George1.   

Abstract

Wiskott-Aldrich syndrome (WAS) is an X linked rare primary immunodeficiency syndrome with an increased propensity for infection, autoimmunity and malignancy. Here we report a male child, who was diagnosed with WAS at 1 year of age following evaluation for symptomatic thrombocytopenia and eczematous skin lesions. He presented later with lymphadenopathy, which was consistent with diffuse large B cell lymphoma on histopathology. He received 6 cycles of R-CHOP chemotherapy for the same and is presently in remission after 6 months. We review the major publications of lymphoma in WAS and discuss the pathological findings, treatment and prognosis of lymphoma in WAS.

Entities:  

Keywords:  Diffuse large B cell lymphoma; Primary immunodeficiency syndrome; Wiskott-Aldrich syndrome

Year:  2014        PMID: 25332606      PMCID: PMC4192205          DOI: 10.1007/s12288-014-0377-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  28 in total

1.  Development of diffuse large cell lymphoma from follicular lymphoma with multiple immunoglobulin heavy chain gene rearrangement occurring in a patient with Wiskott-Aldrich syndrome.

Authors:  Keiki Kawakami; Motoko Yamaguchi; Yasuyuki Watanabe; Tetsuya Murata
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  The development of malignancy in the course of the Aldrich syndrome.

Authors:  R W ten Bensel; E M Stadlan; W Krivit
Journal:  J Pediatr       Date:  1966-05       Impact factor: 4.406

3.  Long-term survival following non-Hodgkin's lymphoma arising in Wiskott-Aldrich syndrome.

Authors:  D Gilson; R E Taylor
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

4.  Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin.

Authors:  G Jayandharan; A Viswabandya; S Baidya; S C Nair; R V Shaji; B George; M Chandy; A Srivastava
Journal:  J Thromb Haemost       Date:  2005-05-09       Impact factor: 5.824

5.  Malignant lymphoma of the jejunum in a patient with Wiskott-Aldrich syndrome. Surgical treatment.

Authors:  R P Faraci; H J Hoffstrand; F G Witebsky; R M Blaese; R M Beazley
Journal:  Arch Surg       Date:  1975-02

6.  Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome.

Authors:  M Nakanishi; H Kikuta; K Tomizawa; K Kojima; A Ishizaka; M Okano; Y Sakiyama; S Matsumoto
Journal:  Cancer       Date:  1993-08-15       Impact factor: 6.860

Review 7.  The Wiskott-Aldrich syndrome.

Authors:  J S Orange; K D Stone; S E Turvey; K Krzewski
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

8.  Hodgkin's disease occurring in a patient with the Wiskott-Aldrich syndrome.

Authors:  P Periman; T R Callihan; L Lessin; G W King; M Blaese
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

9.  Malignant lymphoma in patients with the Wiskott-Aldrich syndrome.

Authors:  J D Cotelingam; F G Witebsky; S M Hsu; R M Blaese; E S Jaffe
Journal:  Cancer Invest       Date:  1985       Impact factor: 2.176

10.  X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene.

Authors:  A Villa; L Notarangelo; P Macchi; E Mantuano; G Cavagni; D Brugnoni; D Strina; M C Patrosso; U Ramenghi; M G Sacco
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

View more
  4 in total

1.  IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo.

Authors:  Joanna S Kritikou; Carin I M Dahlberg; Marisa A P Baptista; Arnika K Wagner; Pinaki P Banerjee; Lavesh Amar Gwalani; Cecilia Poli; Sudeepta K Panda; Klas Kärre; Susan M Kaech; Fredrik Wermeling; John Andersson; Jordan S Orange; Hanna Brauner; Lisa S Westerberg
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

2.  Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53± murine model.

Authors:  Marton Keszei; Joanna S Kritikou; Deborah Sandfort; Minghui He; Mariana M S Oliveira; Hannah Wurzer; Raoul V Kuiper; Lisa S Westerberg
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

3.  Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells.

Authors:  Joanna S Kritikou; Mariana Ms Oliveira; Julien Record; Mezida B Saeed; Saket M Nigam; Minghui He; Marton Keszei; Arnika K Wagner; Hanna Brauner; Anton Sendel; Saikiran K Sedimbi; Stamatina Rentouli; David P Lane; Scott B Snapper; Klas Kärre; Peter Vandenberghe; Jordan S Orange; Lisa S Westerberg
Journal:  JCI Insight       Date:  2021-03-22

4.  Primary Immunodeficiency Disorders in India-A Situational Review.

Authors:  Ankur Kumar Jindal; Rakesh Kumar Pilania; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2017-06-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.